105655-99-0
Chemical Structure
NK-611
Synonym(s): VP 19
- CAS No.: 105655-99-0
- Formula:C31H37NO12
- Molecular Weight:615.62
IUPAC Name: (5R,5aR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7-(dimethylamino)-8-hydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one
InChIKey: ZKSNZYLCOXUJIR-VOKUKXJJSA-N
SMILES: O=C1[C@]2([H])[C@H](C3=CC(OC)=C(O)C(OC)=C3)C4=CC(OCO5)=C5C=C4[C@@H](O[C@@]6([H])[C@@H]([C@H]([C@@]7([H])[C@](CO[C@@H](C)O7)([H])O6)O)N(C)C)[C@@]2([H])CO1
Biological Activity: NK-611 (VP 19) is an epipodophyllotoxin derivative. NK-611 induces DNA double-strand breaks by inhibiting topoisomerase II (IC50 = 56 μM). NK-611 does not inhibit microtubule polymerization, thus avoiding the side effects of the parent compound, Podofilox (HY-15552). NK-611 exhibits broad-spectrum antitumor activity and demonstrates potent efficacy in in vivo models of leukemia. NK-611 can be used in cancer research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NK-611 | NK-611 (VP 19) is an epipodophyllotoxin derivative. NK-611 induces DNA double-strand breaks by inhibiting topoisomerase II (IC50 = 56 μM). NK-611 does not inhibit microtubule polymerization, thus avoiding the side effects of the parent compound, Podofilox (HY-15552). NK-611 exhibits broad-spectrum antitumor activity and demonstrates potent efficacy in in vivo models of leukemia. NK-611 can be used in cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Daley L, et al. Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611. J Med Chem. 1998 Nov 5;41(23):4475-85. [Content Brief]
- [2]. Hanauske AR, et al. Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. Eur J Cancer. 1995 Sep;31A(10):1677-81. [Content Brief]
